No significantly increased risk of AEs with bivalent HPV vaccine

被引:0
|
作者
机构
关键词
D O I
10.1007/s40278-018-51352-y
中图分类号
学科分类号
摘要
引用
收藏
页码:8 / 8
相关论文
共 50 条
  • [3] The remarkable impact of bivalent HPV vaccine in Scotland
    Brotherton, Julia M. L.
    BMJ-BRITISH MEDICAL JOURNAL, 2019, 365
  • [5] Bivalent vaccine against HPV is effective for 4.5 years
    Harper, D. M.
    Franco, E. L.
    Wheeler, C. M.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2006, 73 (07) : 609 - 609
  • [6] Confirming cross-protection of bivalent HPV vaccine
    Brotherton, Julia M. L.
    LANCET INFECTIOUS DISEASES, 2017, 17 (12): : 1227 - 1228
  • [7] Proliferative verrucous vs conventional leukoplakia: no significantly increased risk of HPV infection
    Campisi, G
    Giovannelli, L
    Ammatuna, P
    Capra, G
    Colella, G
    Di Liberto, C
    Gandolfo, S
    Pentenero, M
    Carrozzo, M
    Serpico, R
    D'Angelo, M
    ORAL ONCOLOGY, 2004, 40 (08) : 835 - 840
  • [8] Bivalent AS04-adjuvanted HPV vaccine provides optimal cancer prevention for HPV types not included in the vaccine
    Beyer, Walter E. P.
    Osterhaus, Albert D. M. E.
    VACCINE, 2020, 38 (47) : 7414 - 7416
  • [9] The Health Technology Assessment of bivalent HPV vaccine Cervarix® in Italy
    La Torre, Giuseppe
    de Waure, Chiara
    Chiaradia, Giacomina
    Mannocci, Alice
    Capri, Stefano
    Ricciardi, Walter
    VACCINE, 2010, 28 (19) : 3379 - 3384
  • [10] Bivalent HPV Recombinant Vaccine (Cervarix) for the Prevention of Cervical Cancer
    Schauner, Stephanie
    Lyon, Corey
    AMERICAN FAMILY PHYSICIAN, 2010, 82 (12) : 1541 - +